Literature DB >> 20843795

NMR structure of the first extracellular domain of corticotropin-releasing factor receptor 1 (ECD1-CRF-R1) complexed with a high affinity agonist.

Christy Rani R Grace1, Marilyn H Perrin, Jozsef Gulyas, Jean E Rivier, Wylie W Vale, Roland Riek.   

Abstract

The corticotropin-releasing factor (CRF) peptide hormone family members coordinate endocrine, behavioral, autonomic, and metabolic responses to stress and play important roles within the cardiovascular, gastrointestinal, and central nervous systems, among others. The actions of the peptides are mediated by activation of two G-protein-coupled receptors of the B1 family, CRF receptors 1 and 2 (CRF-R1 and CRF-R2α,β). The recently reported three-dimensional structures of the first extracellular domain (ECD1) of both CRF-R1 and CRF-R2β (Pioszak, A. A., Parker, N. R., Suino-Powell, K., and Xu, H. E. (2008) J. Biol. Chem. 283, 32900-32912; Grace, C. R., Perrin, M. H., Gulyas, J., Digruccio, M. R., Cantle, J. P., Rivier, J. E., Vale, W. W., and Riek, R. (2007) Proc. Natl. Acad. Sci. U.S.A. 104, 4858-4863) complexed with peptide antagonists provided a starting point in understanding the binding between CRF ligands and receptors at a molecular level. We now report the three-dimensional NMR structure of the ECD1 of human CRF-R1 complexed with a high affinity agonist, α-helical cyclic CRF. In the structure of the complex, the C-terminal residues (23-41) of α-helical cyclic CRF bind to the ECD1 of CRF-R1 in a helical conformation mainly along the hydrophobic face of the peptide in a manner similar to that of the antagonists in their corresponding ECD1 complex structures. Unique to this study is the observation that complex formation between an agonist and the ECD1-CRF-R1 promotes the helical conformation of the N terminus of the former, important for receptor activation (Gulyas, J., Rivier, C., Perrin, M., Koerber, S. C., Sutton, S., Corrigan, A., Lahrichi, S. L., Craig, A. G., Vale, W., and Rivier, J. (1995) Proc. Natl. Acad. Sci. U.S.A. 92, 10575-10579).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20843795      PMCID: PMC2992290          DOI: 10.1074/jbc.M110.121897

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  48 in total

1.  Corticotropin releasing factor (CRF) agonists with reduced amide bonds and Ser7 substitutions.

Authors:  L Cervini; P Theobald; A Corrigan; A G Craig; C Rivier; W Vale; J Rivier
Journal:  J Med Chem       Date:  1999-02-25       Impact factor: 7.446

2.  Crystallography & NMR system: A new software suite for macromolecular structure determination.

Authors:  A T Brünger; P D Adams; G M Clore; W L DeLano; P Gros; R W Grosse-Kunstleve; J S Jiang; J Kuszewski; M Nilges; N S Pannu; R J Read; L M Rice; T Simonson; G L Warren
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1998-09-01

3.  Mapping of the ligand-selective domain of the Xenopus laevis corticotropin-releasing factor receptor 1: implications for the ligand-binding site.

Authors:  F M Dautzenberg; S Wille; R Lohmann; J Spiess
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

4.  The solution structure of HIV-1 Nef reveals an unexpected fold and permits delineation of the binding surface for the SH3 domain of Hck tyrosine protein kinase.

Authors:  S Grzesiek; A Bax; G M Clore; A M Gronenborn; J S Hu; J Kaufman; I Palmer; S J Stahl; P T Wingfield
Journal:  Nat Struct Biol       Date:  1996-04

5.  The ligand-selective domains of corticotropin-releasing factor type 1 and type 2 receptor reside in different extracellular domains: generation of chimeric receptors with a novel ligand-selective profile.

Authors:  F M Dautzenberg; G J Kilpatrick; S Wille; R L Hauger
Journal:  J Neurochem       Date:  1999-08       Impact factor: 5.372

Review 6.  The hypothalamic-pituitary-adrenal axis: what can it tell us about stressors?

Authors:  Antonio Armario
Journal:  CNS Neurol Disord Drug Targets       Date:  2006-10       Impact factor: 4.388

7.  Identification of amino acids in the N-terminal domain of corticotropin-releasing factor receptor 1 that are important determinants of high-affinity ligand binding.

Authors:  S Wille; S Sydow; M R Palchaudhuri; J Spiess; F M Dautzenberg
Journal:  J Neurochem       Date:  1999-01       Impact factor: 5.372

8.  Astressin analogues (corticotropin-releasing factor antagonists) with extended duration of action in the rat.

Authors:  J Rivier; J Gulyas; A Corrigan; V Martinez; A G Craig; Y Taché; W Vale; C Rivier
Journal:  J Med Chem       Date:  1998-12-03       Impact factor: 7.446

9.  Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development.

Authors:  G W Smith; J M Aubry; F Dellu; A Contarino; L M Bilezikjian; L H Gold; R Chen; Y Marchuk; C Hauser; C A Bentley; P E Sawchenko; G F Koob; W Vale; K F Lee
Journal:  Neuron       Date:  1998-06       Impact factor: 17.173

10.  Minimal-size, constrained corticotropin-releasing factor agonists with i-(i+3) Glu-Lys and Lys-Glu bridges.

Authors:  J Rivier; S L Lahrichi; J Gulyas; J Erchegyi; S C Koerber; A G Craig; A Corrigan; C Rivier; W Vale
Journal:  J Med Chem       Date:  1998-07-02       Impact factor: 7.446

View more
  23 in total

Review 1.  Structure and mechanism for recognition of peptide hormones by Class B G-protein-coupled receptors.

Authors:  Kuntal Pal; Karsten Melcher; H Eric Xu
Journal:  Acta Pharmacol Sin       Date:  2012-01-23       Impact factor: 6.150

2.  Secretin family (Class B) G protein-coupled receptors - from molecular to clinical perspectives.

Authors:  David R Poyner; Debbie L Hay
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

3.  Photo-cross-linkers incorporated into G-protein-coupled receptors in mammalian cells: a ligand comparison.

Authors:  Irene Coin; Marilyn H Perrin; Wylie W Vale; Lei Wang
Journal:  Angew Chem Int Ed Engl       Date:  2011-07-12       Impact factor: 15.336

Review 4.  Insights into mechanisms of corticotropin-releasing hormone receptor signal transduction.

Authors:  Dimitris K Grammatopoulos
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 5.  Structural insights into ligand recognition and selectivity for classes A, B, and C GPCRs.

Authors:  Sang-Min Lee; Jason M Booe; Augen A Pioszak
Journal:  Eur J Pharmacol       Date:  2015-05-14       Impact factor: 4.432

Review 6.  Multi-functionality of proteins involved in GPCR and G protein signaling: making sense of structure-function continuum with intrinsic disorder-based proteoforms.

Authors:  Alexander V Fonin; April L Darling; Irina M Kuznetsova; Konstantin K Turoverov; Vladimir N Uversky
Journal:  Cell Mol Life Sci       Date:  2019-08-19       Impact factor: 9.261

Review 7.  Receptor Activity-Modifying Proteins (RAMPs): New Insights and Roles.

Authors:  Debbie L Hay; Augen A Pioszak
Journal:  Annu Rev Pharmacol Toxicol       Date:  2015-10-23       Impact factor: 13.820

Review 8.  Insights into the structure of class B GPCRs.

Authors:  Kaspar Hollenstein; Chris de Graaf; Andrea Bortolato; Ming-Wei Wang; Fiona H Marshall; Raymond C Stevens
Journal:  Trends Pharmacol Sci       Date:  2013-12-18       Impact factor: 14.819

9.  Evidence that the thyroid-stimulating hormone (TSH) receptor transmembrane domain influences kinetics of TSH binding to the receptor ectodomain.

Authors:  Chun-Rong Chen; Sandra M McLachlan; Basil Rapoport
Journal:  J Biol Chem       Date:  2010-12-28       Impact factor: 5.157

10.  Genetically encoded chemical probes in cells reveal the binding path of urocortin-I to CRF class B GPCR.

Authors:  Irene Coin; Vsevolod Katritch; Tingting Sun; Zheng Xiang; Fai Yiu Siu; Michael Beyermann; Raymond C Stevens; Lei Wang
Journal:  Cell       Date:  2013-11-27       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.